Skip to main content
. 2018 Aug 6;8:11739. doi: 10.1038/s41598-018-30168-4

Table 3.

Association between the OCT4 and NANOG phenotypes with clinicopathologic parameters.

OCT4/NANOG Phenotypes
Patients and Tumor Characteristics Total No.Cases 186 (N %) Condition1 *P value Condition2 *P value Condition3 *P value
Group1 Group2 Group1 Group2 Group1 Group2
OCT4Nuclearhigh/NANOG-Nuclearhigh or OCT4Nuclearhigh/NANOG-Cytoplasmichigh Other phenotypes OCT4-Nuclearhigh/NANOG Nuclearhigh Other phenotypes OCT4Nuclearhigh/NANOG-Cytoplasmichigh Other phenotypes
RCC subtypes
ccRCC 126 (67.7) 57 (30.6) 69 (37.1) 0.012 34 (18.3) 92 (49.5) 0.116 53 (28.5) 73 (39.2) 0.004
ChRCC 29 (15.6) 22 (11.8) 7 (3.8) 13 (7.0) 16 (8.6) 22 (11.8) 7 (3.8)
pRCC 31 (16.7) 16 (8.6) 15 (8.1) 12 (6.5) 19 (10.2) 14 (7.5) 17 (9.1)
Tumor size (cm)
<4 35 (18.8) 14 (7.5) 21 (11.3) 0.016 9 (4.8) 26 (14.0) 0.503 14 (7.5) 21 (11.3) 0.009
04-Jul 65 (34.9) 28 (15.1) 37 (19.9) 18 (9.7) 47 (25.3) 24 (12.9) 41 (22.0)
07-Oct 44 (23.7) 23 (12.4) 21 (11.3) 15 (8.1) 27 (14.5) 22 (11.8) 22 (11.8)
>10 42 (22.6) 30 (16.1) 12 (6.5) 59 (31.7) 27 (14.7) 29 (15.6) 13 (7.0)
Primary tumor (PT) Stage
I/II 74 (39.8) 35 (18.9) 38 (20.5) 0.547 21 (11.4) 52 (28.1) 0.52 31 (16.8) 42 (22.7) 0.231
III/IV 112 (60.2) 60 (32.4) 52 (28.1) 38 (20.5) 74 (40.0) 58 (31.4) 54 (29.2)
Histological Grade
I/II 94 (50.5) 38 (24.2) 56 (35.7) 0.7 23 (14.6) 71 (45.2) 0.111 34 (21.7) 60 (38.2) 0.05
III/IV 63 (33.9) 35 (22.3) 28 (17.8) 23 (14.6) 40 (25.5) 33 (21.0) 30 (19.1)
Microvascular invasion(MVI)
Positive 38 (20.4) 25 (14.2) 13 (7.4) 0.03 16 (9.1) 22 (12.5) 0.345 24 (13.6) 14 (8.0) 0.076
Negative 132 (71.0) 61 (34.7) 71 (40.3) 39 (22.2) 93 (52.8) 58 (33.0) 74 (42.0)

*Significances are based on Pearson Chi-square test.

Values in bold are statistically significant.

ccRCC indicates clear cell Renal Cell Carcinoma; chRCC, chromophob Renal Cell Carcinoma; pRCC, papillary Renal Cell Carcinoma.